Why is Replimune stock surging today?
Replimune (REPL) shares rose 15.3% to about $13.90, near a 52-week high, after an Aug. 6 FDA accelerated approval for TUDRIQEV with Bristol Myers Squibb’s nivolumab in advanced cutaneous melanoma. The move also followed a $150 million equity offering at $12.06 per share and ahead of fiscal Q4 2026 earnings. Analysts cited higher targets and upgrades.
How this was made
The 30-second read
Why it matters
Today’s move is attributed to three same-day catalysts: FDA accelerated approval, fiscal Q4 2026 earnings, and a newly priced $150M underwritten public offering. The market appears to be pricing a credible path from approval to commercial revenue, despite the need for confirmatory Phase 3 data.
Market read
A biotech-specific regulatory win plus immediate financing and earnings creates a tradable catalyst stack, with volatility likely around the offering close and management’s commercialization narrative.
What to watch
The article highlights accelerated approval but does not provide confirmatory trial timelines or revenue guidance details, which may drive post-earnings re-rating once the initial FDA headline fades.
Background
Replimune’s TUDRIQEV (engineered oncolytic virus) had been rejected twice before, and the FDA granted accelerated approval on Aug 6 in combination with Bristol Myers Squibb’s nivolumab for advanced cutaneous melanoma after prior anti-PD-1 therapy.
Ticker impact
Replimune surged after FDA accelerated approval for TUDRIQEV plus nivolumab, alongside same-day fiscal Q4 earnings and a priced $150M equity offering.
Near-term bullish bias with elevated volatility into and after the Aug 11 offering close and the earnings discussion.
The article cites a first-ever oncolytic virus approval with a checkpoint inhibitor, a same-day priced offering, and bullish analyst actions, all of which are direct catalysts for REPL’s trading.
Market effects
Positive read-through for oncolytic virus and checkpoint-combination oncology peers, though confirmatory Phase 3 remains a key overhang for the group.
Limited, as the article notes major US indices were flat to slightly down while REPL moved sharply.
Modest, primarily a US biotech-specific catalyst rather than a broad macro driver.
Counterpoint
The $150M offering could pressure the stock if investors focus on dilution or if commercial launch assumptions prove too optimistic versus confirmatory Phase 3 data.
Key entities
- companyReplimune
Subject of the article; stock surged on FDA approval, earnings, and a priced equity offering.
- drugTUDRIQEV
Engineered oncolytic virus granted accelerated approval with nivolumab for unresectable advanced cutaneous melanoma.
- companyBristol Myers Squibb
Nivolumab partner named in the FDA approval combination.
- underwriterLeerink Partners
Underwrote the $150M public offering mentioned in the article.
- underwriterJ.P. Morgan
Underwrote the $150M public offering mentioned in the article.
